July 24, 2024

Recently, BOCG's portfolio company, Innorna, announces that China National Medical Products Administration (NMPA) has granted a Drug Clinical Trial Approval Notice for its self-developed Herpes Zoster (HZ) mRNA vaccine IN001; meanwhile, U.S. FDA orphan drug designation granted to IN022 for the Treatment of Homocystinuria after it was granted rare pediatric disease designatio.

July 17, 2024

On July 12, 2024, Mr. Frank Yang, founding partner & CEO of Blue Ocean Capital Group, was invited by the HK Bio-Med Innotech Association and the Hong Kong Productivity Council to lecture in Hong Kong for entrepreneurs, scientists, and managers in the biopharmaceutical industry.

July 9, 2024

BOCG's portfolio company Innorna has been granted the U.S. FDA Rare Pediatric Disease Designation (RPDD) for IN022, their investigational therapy for treating classic homocystinuria (HCU).

December 1, 2023

China’s Best Impact Investments of the Year Awards were solemnly announced, with BOCG winning the “2023 For Good Award | Top 10 Impact Investment Institution”. Dr. Yanling Wen, Chief Medical Officer of BOCG, was invited to participate in a roundtable forum to discuss the challenges and opportunities of ESG impact investment in China.

July 1, 2022

Four well-achieved experts with industry, academic and clinical background respectively, have joined its Scientific and Industrial Advisory Board ("The Advisory Board") to strengthen its investment and operational capabilities. They are Dr. Yan Shao, Dr. Yongqin Zeng, Prof. Jixi Li and Prof. Yanling Wen.

April 11, 2022

BOCG has become an official signatory to the United Nations-supported Principles for Responsible Investment ("UN PRI"). As one of the Chinese leading investment firms focusing on healthcare sector to join UN PRI, BOCG is committed to promoting responsible investment and empowering sustainable development of the portfolio companies.